Michael Benatar1, Joanne Wuu1, Peter M Andersen2, Vittoria Lombardi3, Andrea Malaspina3. 1. Department of Neurology, University of Miami, Miami, FL. 2. Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden. 3. Neuroscience Center, Blizard, Institute of Cell and Molecular Medicine, Barts & the London School of Medicine & Dentistry, London, United Kingdom.
Abstract
OBJECTIVE: To evaluate neurofilament light (NfL) as a biomarker of the presymptomatic phase of amyotrophic lateral sclerosis (ALS). METHODS: The study population includes 84 individuals at risk for developing ALS, 34 controls, 17 ALS patients, and 10 phenoconverters (at-risk individuals observed both before and after the emergence of clinically manifest disease). At-risk individuals are enrolled through Pre-Symptomatic Familial ALS (Pre-fALS), a longitudinal natural history and biomarker study of individuals who are carriers of any ALS-associated gene mutation (in SOD1, C9orf72, TARDBP, FUS, VCP, etc), but who, at the time of enrollment, demonstrated no clinical symptoms or signs (including electromyographic evidence) of manifest disease. NfL in serum and cerebrospinal fluid (CSF) were quantified using an electrochemiluminescence immunoassay. RESULTS: Serum and CSF NfL are substantially higher in ALS patients compared to controls and at-risk individuals and remain relatively stable over time. Among phenoconverters, however, NfL levels were elevated (ie, above the range observed in controls) as far back as ∼12 months preceding the emergence of the earliest clinical symptoms or signs of disease. INTERPRETATION: Serum (and CSF) NfL are informative biomarkers of presymptomatic ALS, providing a new tool to quantify presymptomatic disease progression and to potentially predict the timing of clinical phenoconversion. As such, quantification of NfL may aid the design and implementation of early therapeutic intervention for affected individuals and/or disease prevention trials for individuals at short-term risk of developing ALS. Ann Neurol 2018 Ann Neurol 2018;83:130-139.
OBJECTIVE: To evaluate neurofilament light (NfL) as a biomarker of the presymptomatic phase of amyotrophic lateral sclerosis (ALS). METHODS: The study population includes 84 individuals at risk for developing ALS, 34 controls, 17 ALSpatients, and 10 phenoconverters (at-risk individuals observed both before and after the emergence of clinically manifest disease). At-risk individuals are enrolled through Pre-Symptomatic Familial ALS (Pre-fALS), a longitudinal natural history and biomarker study of individuals who are carriers of any ALS-associated gene mutation (in SOD1, C9orf72, TARDBP, FUS, VCP, etc), but who, at the time of enrollment, demonstrated no clinical symptoms or signs (including electromyographic evidence) of manifest disease. NfL in serum and cerebrospinal fluid (CSF) were quantified using an electrochemiluminescence immunoassay. RESULTS: Serum and CSF NfL are substantially higher in ALSpatients compared to controls and at-risk individuals and remain relatively stable over time. Among phenoconverters, however, NfL levels were elevated (ie, above the range observed in controls) as far back as ∼12 months preceding the emergence of the earliest clinical symptoms or signs of disease. INTERPRETATION: Serum (and CSF) NfL are informative biomarkers of presymptomatic ALS, providing a new tool to quantify presymptomatic disease progression and to potentially predict the timing of clinical phenoconversion. As such, quantification of NfL may aid the design and implementation of early therapeutic intervention for affected individuals and/or disease prevention trials for individuals at short-term risk of developing ALS. Ann Neurol 2018 Ann Neurol 2018;83:130-139.
Authors: Michael Benatar; Joanne Wuu; Vittoria Lombardi; Andreas Jeromin; Robert Bowser; Peter M Andersen; Andrea Malaspina Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2019-08-21 Impact factor: 4.092
Authors: Iddo Magen; Nancy Sarah Yacovzada; Eran Yanowski; Anna Coenen-Stass; Julian Grosskreutz; Ching-Hua Lu; Linda Greensmith; Andrea Malaspina; Pietro Fratta; Eran Hornstein Journal: Nat Neurosci Date: 2021-10-28 Impact factor: 24.884
Authors: Yo Sasaki; Thomas M Engber; Robert O Hughes; Matthew D Figley; Tong Wu; Todd Bosanac; Rajesh Devraj; Jeffrey Milbrandt; Raul Krauss; Aaron DiAntonio Journal: Exp Neurol Date: 2020-02-19 Impact factor: 5.330
Authors: Adam L Boxer; Michael Gold; Howard Feldman; Bradley F Boeve; Susan L-J Dickinson; Howard Fillit; Carole Ho; Robert Paul; Rodney Pearlman; Margaret Sutherland; Ajay Verma; Stephen P Arneric; Brian M Alexander; Bradford C Dickerson; Earl Ray Dorsey; Murray Grossman; Edward D Huey; Michael C Irizarry; William J Marks; Mario Masellis; Frances McFarland; Debra Niehoff; Chiadi U Onyike; Sabrina Paganoni; Michael A Panzara; Kenneth Rockwood; Jonathan D Rohrer; Howard Rosen; Robert N Schuck; Holly D Soares; Nadine Tatton Journal: Alzheimers Dement Date: 2020-01-06 Impact factor: 21.566
Authors: Michael Benatar; Lanyu Zhang; Lily Wang; Volkan Granit; Jeffrey Statland; Richard Barohn; Andrea Swenson; John Ravits; Carlayne Jackson; Ted M Burns; Jaya Trivedi; Erik P Pioro; James Caress; Jonathan Katz; Jacob L McCauley; Rosa Rademakers; Andrea Malaspina; Lyle W Ostrow; Joanne Wuu Journal: Neurology Date: 2020-05-08 Impact factor: 9.910